FDA approves Ariad's Iclusig for rare leukemias

12/16/2012 | Fox Business · HealthDay News

Ariad Pharmaceuticals obtained accelerated FDA approval for Iclusig, or ponatinib, to treat patients with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. The drug, which was cleared three months ahead of schedule, inhibits certain proteins that promote cancer cell development. Iclusig will be sold with a boxed warning on its label about the risk of blood clots and liver poisoning.

View Full Article in:

Fox Business · HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD